AMGN Ticker Curator

• Target Hikes: Morgan Stanley raises to $326 (from $309), Truist to $325 (from $319), citing Krystexxa patent strength and MariTide obesity...

Amgen bolsters Prolia/Xgeva defenses with latest biosimilar settlement:

• Henlius/Organon concede 26 patents valid and infringed by...

UBS has adjusted its Amgen (AMGN) price target upward to $400 from $390, while maintaining a Buy rating. Bullish vote of confidence amid a 1.12% intraday dip.

Genetic study of 28,000 GLP-1 users reveals DNA differences explain weight loss and side effects variations.

• GLP1R variant adds ~0.7kg weight loss...

Amgen's subcutaneous TEPEZZA data establishes a new gold standard for thyroid eye disease treatment, marking a key pipeline win that bolsters its TED leadership.

Bispecific antibodies market exploding with 180+ companies and 250 drugs in pipeline, spanning oncology and beyond.

• Amgen leads via pioneering...

Major patent victory for Amgen: Henlius/Organon agree all 26 asserted patents are valid, enforceable, and infringed by their denosumab biosimilars...

Partnership & Pipeline Updates

• 🔥 Zai Lab Collaboration: Zai Lab reported ongoing progress in its Phase 3 DLLEVATE trial for ZL-1310 in small...

Amgen enters strategic global clinical collaboration with Zai Lab on ZL-1310 for small cell lung cancer, amid Phase 3 DLLEVATE trial progress—signaling oncology pipeline expansion. Zai shares rebounded 12.57% in 30 days and 19.33% YTD.

• Omnitrope milestone: World's first biosimilar approved in EU 20 years ago, delivering USD 1.9B savings and 118M patient days.
• Overall impact:...

Huge growth ahead for AMGN's bispecific pipeline:

• Global market from $12.4B (2025) to $82.3B (2034) at 23.1% CAGR
• Amgen leads with blockbusters...

Key OrbiMed insights on healthcare growth:

• Drug pricing clarity emerging post-Trump deals with MFN pricing for Medicare/Medicaid
• M&A surge ahead:...

Rising legal risks for Amgen's Tepezza:

• 1,800+ cases consolidated in MDL 3079, Northern District of Illinois
• Bellwether trials slated for mid-late...

Mixed institutional signals in $AMGN Q4 holdings:

• Sumitomo Mitsui cut 2.6% to 1,612,368 shares ($527.74M, 0.30% stake)
• KG&L Capital reduced 76%,...

Valuation Assessment

• 🔥 TEPEZZA and MariTide in Focus: Amgen draws fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye...

Explosive growth ahead: Global oral GLP-1 receptor agonist market valued at $6.8B in 2025, projected to hit $92.4B by 2034 at 38.2% CAGR.

Key...

• Biotech rotation accelerating: ETFs up 32-45% in 6 months, still 27% below highs vs. overvalued AI.
• Key drivers: Lower rates, M&A surge, FDA's 44...

Billionaire Ken Fisher signals strong AMGN conviction:

• One of his 15 most notable moves for 2026
• More than doubled position in Q3/Q4 2025 vs. Q2,...

Pipeline wins reshape AMGN views:

• Phase 3 TEPEZZA subQ data for Thyroid Eye Disease and strong MariTide weight loss draw investor focus amid solid...

Key investor implications from Amgen's completed FORWARD II Phase 4 study:

• Tests every-4-week Krystexxa + methotrexate vs. every-2-weeks for...